# A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

> **NCT02451943** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 509 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Doxorubicin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02451943
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2018-12-05
- **Final completion:** 2024-06-27
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02451943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02451943, "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02451943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*